Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26133050 | 1.00 | ADRB1 (0.55) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| SCHEMBL21916491 | 0.86 | ADRB1 (0.46) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| SCHEMBL16081355 | 0.79 | ADRB1 (0.55) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| SCHEMBL13979172 | 0.79 | ADRB1 (0.67) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| SCHEMBL17404733 | 0.74 | ADRB1 (0.61) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| SCHEMBL16077979 | 0.73 | ADRB1 (0.51) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| SCHEMBL20425360 | 0.73 | ADRB1 (0.51) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| SCHEMBL20397508 | 0.73 | ADRB1 (0.46) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| SCHEMBL10725084 | 0.71 | ADRB1 (0.69) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| SCHEMBL5852951 | 0.71 | ADRB1 (0.69) | ADRB1LMNACYP2D6MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503553-B2 | Biodegradable drug-polymer conjugate | POLYACTIVA PTY LTD (AU) | 2025-12-23 | — | — | US | disclosed |
| US-20240247106-A1 | BIODEGRADABLE DRUG-POLYMER CONJUGATE | POLYACTIVA PTY LTD (AU) | 2024-07-25 | — | — | US | disclosed |
| US-11787906-B2 | Biodegradable drug-polymer conjugate | POLYACTIVA PTY LTD (AU) | 2023-10-17 | — | — | US | disclosed |
| US-11787906-B2 | Biodegradable drug-polymer conjugate | POLYACTIVA PTY LTD (AU) | 2023-10-17 | — | — | US | disclosed |
| US-11787906-B2 | Biodegradable drug-polymer conjugate | POLYACTIVA PTY LTD (AU) | 2023-10-17 | — | — | US | disclosed |
| US-20200123322-A1 | BIODEGRADABLE DRUG-POLYMER CONJUGATE | POLYACTIVA PTY LTD (AU) | 2020-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240247106-A1 | BIODEGRADABLE DRUG-POLYMER CONJUGATE | ADRB3, PTGER3, CHRNE | ADRB1 15/4885LMNA 477/4885CYP2D6 96/4885 |
| US-20200123322-A1 | BIODEGRADABLE DRUG-POLYMER CONJUGATE | ADRB3, PTGER3, CHRNE | ADRB1 15/4885LMNA 477/4885CYP2D6 96/4885 |
| US-11787906-B2 | Biodegradable drug-polymer conjugate | ADRB3, PTGER3, CHRM3 | ADRB1 13/4885LMNA 444/4885CYP2D6 102/4885 |
| US-12503553-B2 | Biodegradable drug-polymer conjugate | ADRB3, PTGER3, CHRNE | ADRB1 15/4885LMNA 477/4885CYP2D6 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.